Company intelligence / Profile preview
Sinphar Pharmaceutical
Dongshan Township, Yilan County, Taiwansinphar.com.tw ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Sinphar has a broad commercial portfolio in Taiwan and Asia with multiple approved drugs. Its R&D pipeline includes small molecules and herbal medicines targeting oncology and ophthalmic indications. Notable clinical-stage assets include SB04 for dry age-related macular degeneration (Phase 3), paclitaxel for triple negative breast cancer (Phase 3), SCB‑01A for head and neck neoplasms (Phase 2), GF159 for brain diseases (clinical stage unspecified), SB02 for neoplasms (preclinical). The company also develops health foods/supplements and medical cosmetology products.
- Therapeutic areas
- GastroenterologyOphthalmologyEndocrinologyDermatologyOtherWomen's HealthOncologyNeurology
- Modalities
- Small moleculeHerbal medicineChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Sinphar Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinphar Pharmaceutical.